{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-275902","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.573509+00:00","generated_at":"2026-05-16T21:26:02.209593+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artiva reports AlloNK shows deep B-cell depletion in 32 autoimmune patients; FDA interaction planned 1H 2026","bullets":["32 patients dosed with AlloNK + anti-CD20 mAb as outpatients at community rheumatology sites; no CRS, ICANS or GvHD.","No Grade 3+ AlloNK-related TEAEs, no discontinuations; only one hospitalization (unrelated skin infection).","All 23 analyzed patients had undetectable peripheral CD19+ B-cells by Day 13; high-sensitivity assay confirms depletion.","B-cell depletion depth comparable to CD19-auto-CAR-T, greater than rituximab alone per published studies.","Plans to share initial RA response data from >15 patients and align with FDA on pivotal trial design in 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-275902","json":"https://secwatch.observer/filing/0001193125-25-275902.json","markdown":"https://secwatch.observer/filing/0001193125-25-275902.md","text":"https://secwatch.observer/filing/0001193125-25-275902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525275902/0001193125-25-275902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525275902/artv-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:26:02.209593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}